Logo

Celgene to Present Results of Two P-III Trial SUNBEAM and RADIANCE Part B for Ozanimod to Treat RMS at ECTRIMS 2018

Share this
Celgene to Present Results of Two P-III Trial SUNBEAM and RADIANCE Part B for Ozanimod to Treat RMS at ECTRIMS 2018

Celgene to Present Results of Two P-III Trial SUNBEAM and RADIANCE Part B for Ozanimod to Treat RMS at ECTRIMS 2018

Shots:
  • The two P-III trials SUNBEAM (N=1346) and RADIANCE (N=1320) involves assessing of two doses of ozanimod PO (0.92 & 0.46 mg- equivalent to 1 & 0.5 mg ozanimod HCI) vs 1L Avonex in RMS patients for @12 mos. & @24 mos. respectively
  • P-III SUNBEAM & RADIANCE Part B results: early & advance RMS (1 &0.5mg vs IFN): ARR@12mos. (0.149-0.217; 0.200- 0.277 vs 0.285-0.363); mean number of gadolinium-enhancing(GdE) (0.263- 0.278; 0.458- 0.32 vs 0.656- 0.915); mean number of new or enlarging T2 lesions (2.952- 2.514; 3.744- 2.903 vs 4.633- 4.710)
  • Ozanimod is PO sphingosine 1-phosphate 1 (S1P1) and 5 (S1P5) receptor modulator indicated to treat RMS- UC and Crohn's disease. Avonex (IFN) is a interferon beta-1a used to treat MS
  Ref: Celgene | Image Fierce Pharma

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions